Abstract

Cisplatin (cis-diammine dichloroplatinum), an effective chemotherapeutic agent that is being increasingly used against solid tumors, frequently causes renal impairment and electrolyte disturbances in man, particularly hypomagnesemia and renal magnesium wasting (1,2,3,4). In one report, 76% of patients became hypomagnesemic during cisplatin therapy and of these 50% had remained persistently hypomagnesemic for as long as 3 years following discontinuation of cisplatin treatment (4). The pathogenesis and mechanism(s) of hypomagnesemia and inappropriate renal magnesium wasting induced by cisplatin is still unknown.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call